Touchstone Capital Inc. Invests $5.66 Million in Edwards Lifesciences Co. (NYSE:EW)

Touchstone Capital Inc. acquired a new position in Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 74,241 shares of the medical research company’s stock, valued at approximately $5,661,000. Edwards Lifesciences makes up 5.4% of Touchstone Capital Inc.’s holdings, making the stock its 7th largest holding.

A number of other institutional investors and hedge funds also recently modified their holdings of EW. Advisors Asset Management Inc. boosted its position in Edwards Lifesciences by 0.3% in the 1st quarter. Advisors Asset Management Inc. now owns 43,556 shares of the medical research company’s stock valued at $5,127,000 after buying an additional 117 shares during the last quarter. Apollon Wealth Management LLC boosted its position in Edwards Lifesciences by 1.0% in the 1st quarter. Apollon Wealth Management LLC now owns 12,487 shares of the medical research company’s stock valued at $1,033,000 after buying an additional 119 shares during the last quarter. Geller Advisors LLC lifted its stake in shares of Edwards Lifesciences by 6.5% in the 1st quarter. Geller Advisors LLC now owns 1,965 shares of the medical research company’s stock valued at $231,000 after purchasing an additional 120 shares during the period. Legacy Wealth Asset Management LLC lifted its stake in shares of Edwards Lifesciences by 0.8% in the 4th quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock valued at $1,293,000 after purchasing an additional 134 shares during the period. Finally, KCM Investment Advisors LLC lifted its stake in shares of Edwards Lifesciences by 2.7% in the 1st quarter. KCM Investment Advisors LLC now owns 5,392 shares of the medical research company’s stock valued at $635,000 after purchasing an additional 142 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $95.53 on Friday. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The firm has a market capitalization of $57.50 billion, a price-to-earnings ratio of 41.53, a PEG ratio of 4.72 and a beta of 1.05. The business has a 50-day simple moving average of $85.90 and a 200 day simple moving average of $75.99. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, meeting analysts’ consensus estimates of $0.64. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The firm’s revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.64 EPS. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 14,500 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $91.01, for a total value of $1,319,645.00. Following the transaction, the vice president now owns 39,503 shares in the company, valued at approximately $3,595,168.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, VP Donald E. Bobo, Jr. sold 14,500 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $91.01, for a total value of $1,319,645.00. Following the sale, the vice president now owns 39,503 shares of the company’s stock, valued at approximately $3,595,168.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $91.68, for a total transaction of $1,320,192.00. Following the completion of the sale, the vice president now directly owns 173,584 shares in the company, valued at approximately $15,914,181.12. The disclosure for this sale can be found here. In the last quarter, insiders sold 182,349 shares of company stock worth $15,334,555. Insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on EW. Stifel Nicolaus raised their price objective on Edwards Lifesciences from $70.00 to $83.00 and gave the stock a “hold” rating in a research note on Wednesday, February 7th. Evercore ISI cut Edwards Lifesciences from an “outperform” rating to an “in-line” rating and reduced their price target for the company from $80.00 to $77.00 in a research report on Thursday, January 4th. Wells Fargo & Company raised Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price target for the company in a research report on Friday, February 2nd. Oppenheimer increased their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, March 18th. Finally, Royal Bank of Canada increased their price target on Edwards Lifesciences from $82.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $88.80.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.